Peripheral GRN mRNA and Serum Progranulin Levels as a Potential Indicator for Both the Presence of Splice Site Mutations and Individuals at Risk for Frontotemporal Dementia.


Journal

Journal of Alzheimer's disease : JAD
ISSN: 1875-8908
Titre abrégé: J Alzheimers Dis
Pays: Netherlands
ID NLM: 9814863

Informations de publication

Date de publication:
2019
Historique:
pubmed: 27 11 2018
medline: 3 3 2020
entrez: 27 11 2018
Statut: ppublish

Résumé

Progranulin (GRN) gene mutations are a major cause of frontotemporal dementia (FTD). Most mutations identified to date are null mutations, which are predicted to cause the pathology via haploinsufficiency. Decreased peripheral progranulin protein (PGRN) levels are associated with the presence of GRN null mutations and are accepted as reliable biomarkers. In this study, our aim was to test whether the presence of specific GRN splice site mutations (c.- 8+2T>G and c.708+6_9del), could be predicted by peripheral mRNA or protein GRN levels, by studying affected and asymptomatic individuals from FTD families. We also tested four missense GRN variants to assess if altered GRN levels depended on the type of mutation.Our results confirmed a reduction in both mRNA and protein PGRN levels in the splice site mutation carriers, which is consistent with previous reports for null mutations. Our results also suggested that both decreased peripheral GRN mRNA and serum PGRN levels indicate the presence of pathogenic mutations in affected individuals, and identify the asymptomatic individuals at risk, without previous knowledge of genetic status. Both inferences suggest a potential use of peripheral GRN mRNA or serum PGRN levels as biomarkers for families with FTD.

Identifiants

pubmed: 30475763
pii: JAD180599
doi: 10.3233/JAD-180599
pmc: PMC6422018
mid: NIHMS1010955
doi:

Substances chimiques

Biomarkers 0
GRN protein, human 0
Progranulins 0
RNA Splice Sites 0
RNA, Messenger 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

159-167

Subventions

Organisme : Medical Research Council
ID : MR/K01417X/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : G1001253
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L501542/1
Pays : United Kingdom
Organisme : Intramural NIH HHS
ID : Z99 AG999999
Pays : United States
Organisme : Parkinson's UK
ID : G-0907
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/J004758/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0701075
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0901254
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N026004/1
Pays : United Kingdom
Organisme : Parkinson's UK
ID : G-1307
Pays : United Kingdom

Références

Brain. 2009 Mar;132(Pt 3):583-91
pubmed: 19158106
Arch Neurol. 2007 Oct;64(10):1436-46
pubmed: 17923627
Neurodegener Dis. 2012;9(3):121-7
pubmed: 22123177
J Neurochem. 2010 Mar;112(5):1305-15
pubmed: 20028451
PLoS One. 2016 Sep 15;11(9):e0162592
pubmed: 27632209
Mov Disord. 2017 Mar;32(3):476-478
pubmed: 27859661
Neurobiol Aging. 2018 Feb;62:245.e9-245.e12
pubmed: 29146050
Dement Geriatr Cogn Dis Extra. 2016 Jul 22;6(2):330-340
pubmed: 27703466
PLoS One. 2012;7(10):e46688
pubmed: 23056405
Nat Methods. 2010 Apr;7(4):248-9
pubmed: 20354512
Nature. 2006 Aug 24;442(7105):916-9
pubmed: 16862116
Nature. 2006 Aug 24;442(7105):920-4
pubmed: 16862115
Neurodegener Dis. 2014;13(4):214-23
pubmed: 24022032
Ann Neurol. 2009 May;65(5):603-9
pubmed: 19288468
JAMA Neurol. 2013 Mar 1;70(3):365-73
pubmed: 23338682
J Neuropathol Exp Neurol. 2014 May;73(5):467-73
pubmed: 24709683
Neurobiol Aging. 2009 Nov;30(11):1825-33
pubmed: 18314228
JAMA Neurol. 2013 Jun;70(6):774-8
pubmed: 23609919
J Mol Med (Berl). 2003 Oct;81(10):600-12
pubmed: 12928786
J Comput Biol. 2004;11(2-3):377-94
pubmed: 15285897
Hum Mutat. 2007 Sep;28(9):846-55
pubmed: 17436289
Neurology. 2008 Oct 14;71(16):1235-9
pubmed: 18768919
Acta Neuropathol Commun. 2015 Nov 10;3:68
pubmed: 26555887
Neurology. 2008 Aug 26;71(9):656-64
pubmed: 18565828
J Alzheimers Dis. 2010;22(3):981-4
pubmed: 20858962
Alzheimer Dis Assoc Disord. 2011 Apr-Jun;25(2):173-8
pubmed: 20975516
Neurology. 2008 Jul 22;71(4):253-9
pubmed: 18184915
Neuropsychiatr Dis Treat. 2018 Feb 26;14:657-662
pubmed: 29520145
Ann Neurol. 2008 Jul;64(1):92-6
pubmed: 18551524
Alzheimers Dement (Amst). 2017 May 29;9:10-20
pubmed: 28653036
Nat Methods. 2014 Apr;11(4):361-2
pubmed: 24681721
J Alzheimers Dis. 2016 May 30;53(2):475-85
pubmed: 27258413

Auteurs

Gamze Guven (G)

Department of Genetics, Aziz Sancar Institute for Experimental Medicine, Istanbul University, Istanbul, Turkey.

Başar Bilgic (B)

Department of Neurology, Behavioural Neurology and Movement Disorders Unit, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.

Zeynep Tufekcioglu (Z)

Department of Neurology, Behavioural Neurology and Movement Disorders Unit, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.

Nihan Erginel Unaltuna (N)

Department of Genetics, Aziz Sancar Institute for Experimental Medicine, Istanbul University, Istanbul, Turkey.

Hasmet Hanagasi (H)

Department of Neurology, Behavioural Neurology and Movement Disorders Unit, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.

Hakan Gurvit (H)

Department of Neurology, Behavioural Neurology and Movement Disorders Unit, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.

Andrew Singleton (A)

Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.

John Hardy (J)

Department of Molecular Neuroscience, Institute of Neurology, University College London, London, UK.

Murat Emre (M)

Department of Neurology, Behavioural Neurology and Movement Disorders Unit, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.

Cagri Gulec (C)

Department of Medical Genetics, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.

Jose Bras (J)

Department of Molecular Neuroscience, Institute of Neurology, University College London, London, UK.
Department of Medical Sciences and Institute of Biomedicine - iBiMED, University of Aveiro, Aveiro, Portugal.
UK Dementia Research Institute at UCL (UK DRI), London, UK.

Rita Guerreiro (R)

Department of Molecular Neuroscience, Institute of Neurology, University College London, London, UK.
Department of Medical Sciences and Institute of Biomedicine - iBiMED, University of Aveiro, Aveiro, Portugal.
UK Dementia Research Institute at UCL (UK DRI), London, UK.

Ebba Lohmann (E)

Department of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tübingen, Germany.
DZNE, German Center for Neurodegenerative Diseases, Tübingen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH